Myeloid Therapeutics has restructured its staff to focus on two clinical-stage programs, Endpoints News reported. Daniel Getts, CEO and co-founder of the Cambridge, Mass.–based immunology company, confirmed the restructuring to Endpoints. He did not tell the media outlet how many employees were laid off but said the changes “particularly” affected Myeloid’s preclinical teams. Myeloid’s two clinical-stage programs are MT-302 and MT-303, both in vivo immune cell programming therapies. The company is studying MT-302 for use in colon, lung and breast cancer and MT-303 for use in liver cancer. Getts told Endpoints that dose escalation is underway for both therapies, which are in Phase I clinical trials. Getts did not identify which programs Myeloid has deprioritized in favor of MT-302 and MT-303. However, according to the company’s website, aside from those two therapies, the pipeline consists of a myeloid cell editing program and a gene editing program. Both are in the discovery stage.
